Is low-molecular-weight heparin superior to aspirin for VTE prophylaxis? Aspirin demonstrated a significantly higher rate of postoperative venous thromboembolic events compared with enoxaparin in this noninferiority study.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      LOW-molecular-weight heparin; ENOXAPARIN; ORTHOPEDIC surgery; ASPIRIN; THROMBOEMBOLISM
    • Abstract:
      The article compares the efficacy of aspirin versus low-molecular-weight heparin (LMWH) for venous thromboembolism (VTE) prophylaxis in patients undergoing total hip or knee arthroplasty. It mentions that the noninferiority study, known as the CRISTAL trial, reveals that aspirin has a significantly higher rate of postoperative VTE compared to enoxaparin, suggesting that LMWH may be a superior choice for VTE prophylaxis in this patient population.